Bile duct disorders

Clinics in Liver Disease

Volumn 7, Issue 2, 2003, Pages 295-309

  Geubel, André P ^a   Sempoux, Christine ^a   Rahier, Jacques ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AMITRIPTYLINE; AMOXICILLIN PLUS CLAVULANIC ACID; ANESTHETIC AGENT; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; AZATHIOPRINE; AZITHROMYCIN; BARBITURIC ACID; BENOXAPROFEN; CARBAMAZEPINE; CARBUTAMIDE; CHLOROTHIAZIDE; CHLORPROMAZINE; CIMETIDINE; CIPROFLOXACIN; CORTICOSTEROID; CYPROHEPTADINE; DANTROLENE; DISULFIRAM; ETRETINATE; FENOFIBRATE; HALOPERIDOL; IMMUNOSUPPRESSIVE AGENT; PROCHLORPERAZINE; TETRACYCLINE; UNINDEXED DRUG; URSODEOXYCHOLIC ACID;

BILE DUCT DISEASE; BILE DUCT OBSTRUCTION; CHOLESTASIS; CHRONIC DISEASE; CLINICAL FEATURE; DISEASE SEVERITY; DRUG INDUCED DISEASE; HUMAN; INCIDENCE; LIVER FAILURE; LIVER TRANSPLANTATION; PATHOPHYSIOLOGY; RADIATION INJURY; REVIEW; SYMPTOMATOLOGY; VANISHING BILE DUCT SYNDROME;

EID: 0038047042     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1089-3261(03)00028-X     Document Type: Review

References (76)

1. Degott C, Feldmann G, Larrey D, et al. Drug-induced prolonged cholestasis in adults: a histological semiquantitative study demonstrating progressive ductopenia. Hepatology 1992;15:244-51.
2. Erlinger S. Drug-induced cholestasis. J Hepatol 1997;26(Suppl 1):1-4.
3. Larrey D, Geneve J, Pessayre D, et al. Prolonged cholestasis after cyproheptadine-induced acute hepatitis. J Clin Gastroenterol 1987;9:102-4.
4. Chitturi S, Farell GC. Drug-induced cholestasis. Semin Gastrointest Dis 2001;12:113-24.
5. Srivastava M, Perez-Atayde A, Jonas MM. Drug-associated acute-onset vanishing bile duct and Stevens-Johnson syndrome in a child. Gastroenterol 1998;115:743-6.
6. Forbes GM, Jeffrey GP, Shilkin KB, et al. Carbamazepine hepatotoxicity: another cause of the vanishing bile duct syndrome. Gastroenterology 1992;102:1385-8.
7. Rosenberg WM, Ryley NG, Trowell JM, et al. Dextropropoxyphene induced hepatotoxicity: a report of nine cases. J Hepatol 1993;19:470-4.
8. Hautekeete M, Brenard R, Horsmans Y, et al. Liver injury related to amoxycillin-clavulanic acid: interlobular bile duct lesions and extrahepatic manifestations. J Hepatol 1995;22:71-7.
9. Geubel AP, Rahier J. Therapy in Liver Diseases - the pathophysiological basis of therapy. In: Arroyo V, Bosch J, Bruguera M, Rodes J, editors. Drug-induced bile duct injury. Barcelona: Masson SA; 1997. p. 239-45.
10. Geubel AP, Sempoux C. Drug and toxin-induced bile duct disorders. J Gastroenterol Hepatol 2000;15:1232-8.
11. Larrey D, Michel H. Pathologie biliaire due aux médicaments. Gastroenterol Clin Biol 1993;17: H59-65.
12. Geubel AP, Nakad A, Rahier J, et al. Prolonged cholestasis and disappearance of interlobular bile duct following chlorpropamide and erythromycin ethylsuccinate. Case of drug interaction? Liver 1988;8:350-3.
13. Ishii M, Miyazaki Y, Yamamoto T, et al. A case of drug-induced ductopenia resulting in fatal biliary cirrhosis. Liver Aug 1993;13:227-31.
14. Ohmoto K, Yamamoto S, Hirokawa M. Symptomatic primary biliary cirrhosis triggered by administration of Sulpiride. Am J Gastroenterol 1999;94:3660-1.
15. Geubel AP. Radiation-induced bile duct injury: a vanishing cause of obstructive jaundice? J Hepatol 1994;20:687-8.
16. Belghiti J, Benhamou JP, Houry S, et al. Caustic sclerosing cholangitis. A complication of the surgical treatment of hydatid disease of the liver. Arch Surg 1986;121:1162-5.
17. Prat F, Guzon D, Trépo C. Cholangite sclérosante secondaire à la stérilisation d'un kyste hydatique du foie par une solution salée hypertonique. Gastroenterol Clin Biol 1988;12:867-9.
18. Tsimoyiannis EC, Grantzis E, Montesidou K, et al. Secondary sclerosing cholangitis after injection of formaldehyde into hydatic cysts of the liver. Eur J Surg 1995;161:299-300.
19. Anderson SD, Nolley HC, Berland LL, et al. Causes of jaundice during hepatic artery infusion chemotherapy. Radiology 1986;161:439-42.
20. Kemeny N, Daby J, Reichman B, et al. Sclerosing cholangitis after continuous hepatic artery in fusion of FUDR. Ann Surg 1985;202:176-81.
21. Maknuchi M, Sukigara M, Mori I, et al. Bile duct necrosis: complication of transcatheter hepatic arterial embolization. Radiology 1985;156:331-4.
22. Alderman S, Kailas S, Goldfarb S, et al. Cholestatis hepatitis after ingestion of chaparral leaf: confirmation by endoscopic retrograde cholangiopancreatography and liver biopsy. J Clin Gastroenterol 1994;19:242-7.
23. Sheikh NM, Philen RM, Love LA. Chaparral-associated hepatotoxicity. Arch Intern Med 1997;158:913-9.
24. Kopelman H, Scheuer PJ, Williams R. The liver lesion of the Epping Jaundice. Q J Med 1966;35:553-62.
25. Horsmans Y, Harvengt C. Secondary drug-induced cholestasis with bile duct involvement. Acta Gastroenterol Belg 1991;54:27-33.
26. Cavanzo FJ, Garcia CF, Botero RC. Chronic cholestasis paucity of bile ducts, red cell aplasia and the Stevens-Johnson syndrome. An ampicillin-associated case. Gastroenterology 1990;99:854-6.
27. Horsmans Y, Rahier J, Geubel AP. Reversible cholestasis with bile duct injury following azathioprine therapy. Liver 1991;11:89-93.
28. Pagliaro L, Campesi G, Aguglia F. Barbiturate jaundice. Report of a case due to a barbital-containing drug, with positive rechallenge to phenobarbital. Gastroenterology 1969;56:938-43.
29. Babbs C, Warnes TW. Primary biliary cirrhosis after benoxaprofen. BMJ 1986;203:241.
30. De Galocsy C, Horsmans Y, Rahier J, et al. Vanishing bile duct syndrome occurring after carbamazepine administration: a second case report. J Clin Gastroenterol 1994;19:269-71.
31. Levy M, Goddman M, Van Dyne BJ, Hatton S. Granulomatous hepatitis secondary to carbamazepine. Ann Intern Med 1981;95:64-5.
32. Husebeye KO. Jaundice with persisting pericholangiolitic inflammation in a patient treated with chlorothiazide. Report of a case. Am J Dig Dis 1964;9:439-46.
33. Ishak KG, Iery NS. Hepatic injury associated with the phenothiazines. Clinico-pathologic and follow-up study of the 36 patients. Arch Pathol 1972;93:293-304.
34. Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. New York: Appleton-Century-Crofts; 1978.
35. Ishak KG. Drug-induced liver injury pathology in AASLD postgraduate course 1998. Clinical and pathological correlations in liver disease: Approaching the Next Millennium. In: Bloomer JF, Goodman ZD, Ishak KG. Drug-induced liver injury. The Armed Forces Institute of Pathology, The American Registry of Pathology, and The American Association for the Study of Liver Diseases: Washington DC; 1998. p. 236-51.
36. Hillino D, Felsenheld C, Obernn P, et al. Pericholangite chez un adulte traité par clométacine. Gastroenterol Clin Biot 1983;7:1038-9.
37. Wilkinson SP, Portmann BB, Williams R. Hepatitis from dantrolene sodium. Gut 1979;20:33-6.
38. Bierbaum C, Neef J, Damaschke HJ, et al. Arzneimittelhepatitis durch Disulfiram (Antabuse®). Z Klin Med 1991;46:275-7.
39. Lazarczyk DA, Duffy MC. Erythromycin-induced primary biliary cirrhosis. Dig Dis Sci 2000;45:1115-8.
40. Khouri MR, Saul SH, Dlugosz HA, et al. Hepatocanicular injury associated with vitamin A derivative etretinate. An idiosyncratic hypersensitivity reaction. Dig Dis Sci 1987;32:1207-11.
41. Lepicart A, Malalt A, Zafrani ES, et al. Atteinte chronique des canaux biliaires interlobulaires induite par le fenofibrate. Gastroenterol Clin Biol 1994;18:1033-5.
42. Kock GH, Stricker BH, Blok AP, et al. Flucoxacillin-associated hepatic injury. Liver 1994;14:225-9.
43. Goodman RC, Dean PJ, Radparvar A, et al. Glybarite-induced hepatitis. Ann Intern Med 1987;106:837-9.
44. Miyazaki IM, Yamamoto Y, Miura M, et al. A case of drug-induced ductopenia resulting in fatal biliary cirrhosis. Liver 1993;13:227-31.
45. Benninger J, Schneider HT, Schuppan D, et al. Acute hepatitis induced by greater celandine (chelidonium majus). Gastroenterol 1999;117:1234-7.
46. Murphy M, Hurst S, McDonald GSA, et al. Intrahepatic cholestasis secondary to gold therapy. Eur J Gastroenterol Hepatol 1991;3:855-9.
47. Myers JL, Augur NA. Hydralazine-induced cholangitis. Gastroenterology 1984;87:1185-8.
48. Alam I, Ferrell LD, Bass NM. Vanishing bile duct syndrome temporally associated with ibuprofen use. Am J Gastroenterol 1996;91:1626-30.
49. Punt CJA, Henzen-Moymans SC, Bolhuis RLH, et al. Hyperbilirubinaemia in patients treated with recombinant human interleukin-2 (rII-2). Br J Cancer 1990;61:491.
50. Adriaensens B, Roskams T, Van Steenbergen W. Hepatotoxicity related to Itraconazole: report of three cases. Acta Clin Belg 2001;56:364-9.
51. Lok ASF, Ng IOL. Prochlorperazine-induced chronic cholestasis. J Hepatol 1988;6:369-73.
52. Mondardini A, Pasquino P, Bernardi P, et al. Propafenone-induced liver injury: report of a case and review of the literature. Gastroenterol 1993;104:1524-6.
53. Lerche A, Vysberg M, Kirkegaard E. Acute cholangitis and pancreatitis associated with sulindac (clinoril®). Histopathology 1987;6:647-53.
54. Mallat A, Zafrani ES, Metreau JM, et al. Terfinafine-induced prolonged cholestasis with reduction of interlobular bile ducts. Dig Dis Sci 1997;42:1486-8.
55. Van't wout JW, Hermann WA, de Vries RA, et al. Terbinafine-associated hepatic injury. J Hepatol 1994;21:115-7.
56. Roy MA, Nugent FW, Aretz HT. Micronodular cirrhosis after thiabendazole. Dig Dis Sci 1989;34:938-41.
57. Le Bricquir Y, Larrey D, Blanc P, et al. Tianeptine - an instance of drug-induced hepatotoxicity predicted by prospective experimental studies. J Hepatol 1994;21:771-3.
58. Wegmann C, Munzenmaier R, Dormann AJ, et al. Ticlopidine-induced acute cholestatic hepatitis. Dtsch Med Wochenschr 1998;123:146-50.
59. Kowdley KV, Keeffe EB, Fawaz KA. Prolonged cholestasis due to trimethoprim sulfamethoxazole. Gastroenterology 1992;102:2148-50.
60. O'Donohue J, Oien KA, Donaldson P, et al. Co-amoxiclav jaundice: clinical and histological features and HLA class II association. Gut 2000;47:717-20.
61. Hautekeete ML, Horsmans Y, Van Waeyenberge C, et al. HLA association of amoxicillin-clavulanate-induced hepatitis. Gastroenterology 1999;117:1181-6.
62. Quattropanic C, Schneider M, Helbling A, et al. Cholangiopathy after short-term administration of piperacillin and imipenem/cilastatin. Liver 2001;21:213-6.
63. Principi N, Esposito S. Comparative tolerability of erythromycin and newer macrolide antibacterials in paediatric patients. Durg Saf 1999;20:25-41.
64. Review by an International Group. Histo-pathology of the intrahepatic biliairy tree. Liver 1983;3:161-75.
65. Desmet VJ. Vanishing bile duct syndrome in drug-induced liver disease. J of Hepatol 1997;26:31-5.
66. Duerksen DR, Van Aerde JE, Gramlich L, et al. Intravenous ursodeoxycholic acid reduces cholestasis in parenterally fed newborn piglets. Gastroenterol 1996;111:1111-7.
67. Jaeschke H, Gores GJ, Cederbaum AI, et al. Mechanisms of hepatotoxicity. Toxicol Sci 2002;65:166-76.
68. Sempoux C, Horsmans Y, Geubel A, et al. Severe radioation-induced liver disease following localized radiation therapy for bilio-pancreatic carcinoma: activation of hepatic stellate cells as an early event. Hepatol 1997;26:128-34.
69. Gruchalla RS. Clinical assessment of drug-induced disease. Lancet 2000;356:1505-11.
70. Pessayre D. Physiopathologie des hépatopathies médicamenteuses. Gastroenterol Clin Biol 1993;17:H3-17.
71. Kiso S, Kaxata S, Imai Y, et al. Efficacy of ursodeoxycholic acid therapy in chronic viral hepatitis C with high serum gamma-glutamyltranspeptidase levels. J Gastroenterol 1996;31:75-80.
72. O'Brien C, Shields DS, Saul SH, et al. Drug-induced vanishing bile duct syndrome: response to ursodiol. Am J Gastroenterol 1996;91:1456-7.
73. Monadpour D, Altorfer J, Flury R, et al. Chlorpromazine-induced vanishing bile duct syndrome leading to biliary cirrhosis. Hepatology 1994;20:1437-41.
74. Hunt CM, Washington K. Tetracycline-induced bile duct paucity and prolonged cholestasis. Gastroenterology 1994;107:1844-7.
75. Farrell GC. Drug-induced hepatic injury. J Gastroenterol Hepatol 1997;12(Suppl):S242-50.
76. Larrey D, Vial T, Micaleff A, et al. Hepatitis associated with amoxycillin-clavulanic acid: combination report of 15 cases. Gut 1992;33:368-71.